Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK-9) Inhibitors Induced Liver Injury - A Retrospective Analysis

Journal of Community Hospital Internal Medicine Perspectives - United Kingdom
doi 10.1080/20009666.2019.1710952
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Lipoprotein(a) and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors

Clinical Research in Cardiology Supplements
Nuclear MedicineRadiologyMolecular BiologyStructural BiologyImagingMedicine
2019English

Lipoprotein(a) and Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2017English

Cost Effectiveness of Proprotein Convertase Subtilisin/ Kexin Type 9 (PCSK9) Inhibitors

Cardiovascular Disorders and Medicine
2019English

Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Do We Have a Vanquishing New Strategy?

European Journal of Preventive Cardiology
EpidemiologyCardiovascular MedicineCardiology
2018English

PCSK6 (Proprotein Convertase Subtilisin/Kexin Type 6)

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2017English

Variations of the Proprotein Convertase Subtilisin/Kexin Type 9 Gene in Coronary Artery Disease

Journal of International Medical Research
BiochemistryMedicineCell Biology
2019English

Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia

Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular MedicineCardiology
2009English

Management of Patients Eligible for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Economic Impact and Reform Proposals

Global and Regional Health Technology Assessment
Health Policy
2019English

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Deficiency Is Protective Against Venous Thrombosis in Mice

Scientific Reports
Multidisciplinary
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy